A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the
Latest Information Update: 25 Feb 2025
Price :
$35 *
At a glance
- Drugs ATB 1651 (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors AmtixBio
- 19 Feb 2025 Status changed from not yet recruiting to recruiting.
- 28 Mar 2024 New trial record